These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16732688)

  • 1. Long-term safety of bisphosphonate therapy for osteoporosis: a review of the evidence.
    Liberman UA
    Drugs Aging; 2006; 23(4):289-98. PubMed ID: 16732688
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date.
    Reginster JY; Malaise O; Neuprez A; Jouret VE; Close P
    Drugs Aging; 2007; 24(5):351-9. PubMed ID: 17503893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of daily and intermittent use of ibandronate on bone mass and bone turnover in postmenopausal osteoporosis: a review of three phase II studies.
    Schimmer RC; Bauss F
    Clin Ther; 2003 Jan; 25(1):19-34. PubMed ID: 12637110
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen.
    Pyon EY
    Clin Ther; 2006 Apr; 28(4):475-90. PubMed ID: 16750461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD
    Clin Ther; 2005 Apr; 27(4):361-76. PubMed ID: 15922811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis : results of FACTS -international.
    Reid DM; Hosking D; Kendler D; Brandi ML; Wark JD; Weryha G; Marques-Neto JF; Gaines KA; Verbruggen N; Melton ME
    Clin Drug Investig; 2006; 26(2):63-74. PubMed ID: 17163237
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bisphosphonates for prevention of postmenopausal osteoporosis.
    Ravn P
    Dan Med Bull; 2002 Feb; 49(1):1-18. PubMed ID: 11894721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of long-term bisphosphonates in postmenopausal osteoporosis.
    Miller PD
    Expert Opin Pharmacother; 2003 Dec; 4(12):2253-8. PubMed ID: 14640924
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug insight: Bisphosphonates for postmenopausal osteoporosis.
    Chapurlat RD; Delmas PD
    Nat Clin Pract Endocrinol Metab; 2006 Apr; 2(4):211-9; quiz following 238. PubMed ID: 16932286
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F; Borges JL; Curiel MD
    Clin Ther; 2007 Jun; 29(6):1116-27. PubMed ID: 17692726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study.
    Miller PD; McClung MR; Macovei L; Stakkestad JA; Luckey M; Bonvoisin B; Reginster JY; Recker RR; Hughes C; Lewiecki EM; Felsenberg D; Delmas PD; Kendler DL; Bolognese MA; Mairon N; Cooper C
    J Bone Miner Res; 2005 Aug; 20(8):1315-22. PubMed ID: 16007327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review.
    Rossini M; Viapiana O; Gatti D; Adami S
    Clin Ther; 2009 Jul; 31(7):1497-510. PubMed ID: 19695399
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety considerations with bisphosphonates for the treatment of osteoporosis.
    Strampel W; Emkey R; Civitelli R
    Drug Saf; 2007; 30(9):755-63. PubMed ID: 17722968
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of bisphosphonates in the management of postmenopausal osteoporosis.
    Papapoulos SE
    Ann N Y Acad Sci; 2011 Feb; 1218():15-32. PubMed ID: 20946579
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term tolerability of the bisphosphonates in postmenopausal osteoporosis: a comparative review.
    Kherani RB; Papaioannou A; Adachi JD
    Drug Saf; 2002; 25(11):781-90. PubMed ID: 12222989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous ibandronate: in the treatment of osteoporosis.
    Croom KF; Scott LJ
    Drugs; 2006; 66(12):1593-601; discussion 1602-3. PubMed ID: 16956306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimizing administration of bisphosphonates in women with postmenopausal osteoporosis.
    Rackoff PJ; Sebba A
    Treat Endocrinol; 2005; 4(4):245-51. PubMed ID: 16053341
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study.
    Reginster JY; Wilson KM; Dumont E; Bonvoisin B; Barrett J
    J Clin Endocrinol Metab; 2005 Sep; 90(9):5018-24. PubMed ID: 15972582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates.
    Cosman F; Gilchrist N; McClung M; Foldes J; de Villiers T; Santora A; Leung A; Samanta S; Heyden N; McGinnis JP; Rosenberg E; Denker AE
    Osteoporos Int; 2016 Jan; 27(1):377-86. PubMed ID: 26556736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.